Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis: From the Women in Innovation and Drug-Eluting Stents Collaborative Patient-Level Pooled Analysis (original) (raw)
Related papers
Objectives: To investigate the safety and efficacy of new-generation drug eluting stents (DES), compared with early-generation DES, in women undergoing complex percutaneous coronary intervention (CPCI). Background: Whether the benefits of new-generation DES are preserved in women undergoing complex percutaneous revascularization is unclear. Methods: We pooled patient-level data from women enrolled in 26 randomized trials of DES. Study population was categorized based on the presence or absence of CPCI, which was defined as the composite of total stent length > 30mm, ≥ 2 stents implanted, ≥ 2 lesions treated or bifurcation lesion as target vessel. The primary endpoint was major adverse cardiovascular events (MACE) defined as a composite of all-cause mortality, myocardial infarction or target lesion revascularization at three years of follow-up. Results: Out of 10,241 women included in the pooled database, 4629 (45%) underwent CPCI. Compared with non-CPCI, women who underwent CPCI ...
JAMA cardiology, 2017
Women with acute myocardial infarction (MI) undergoing mechanical reperfusion remain at increased risk of adverse cardiac events and mortality compared with their male counterparts. Whether the benefits of new-generation drug-eluting stents (DES) are preserved in women with acute MI remains unclear. To investigate the long-term safety and efficacy of new-generation DES vs early-generation DES in women with acute MI. Collaborative, international, individual patient-level data of women enrolled in 26 randomized clinical trials of DES were analyzed between July and December 2016. Only women presenting with an acute coronary syndrome were included. Study population was categorized according to presentation with unstable angina (UA) vs acute MI. Acute MI included non-ST-segment elevation MI (NSTEMI) or ST-segment elevation MI (STEMI). Randomization to early- (sirolimus- or paclitaxel-eluting stents) vs new-generation (everolimus-, zotarolimus-, or biolimus-eluting stents) DES. Composite ...
JACC. Cardiovascular interventions, 2018
The aim of this study was to examine whether stent length per patient and stent length per lesion are negative markers for 3-year outcomes in women following percutaneous coronary intervention (PCI) with new-generation drug-eluting stents (DES). In the era of advanced stent technologies, whether stent length remains a correlate of adverse outcomes is unclear. Women treated with new-generation DES in 14 randomized trials from the WIN-DES (Women in Innovation and Drug-Eluting Stents) pooled database were evaluated. Total stent length per patient, which was available in 5,403 women (quartile 1, 8 to 18 mm; quartile 2, 18 to 24 mm; quartile 3, 24 to 36 mm; quartile 4, ≥36 mm), and stent length per lesion, which was available in 5,232 women (quartile 1, 8 to 18 mm; quartile 2, 18 to 20 mm; quartile 3, 20 to 27 mm; quartile 4, ≥27 mm) were analyzed in quartiles. The primary endpoint was 3-year major adverse cardiovascular events (MACE), defined as a composite of all-cause death, myocardia...
Open heart, 2014
First-generation drug-eluting stents (DES) have become the most widely used devices worldwide for management of coronary artery disease. As remote follow-up data were becoming available, concerns emerged in regard to their long-term safety. Second-generation DES were designed to overcome safety issues, but the results of randomised clinical trials remain conflicting. We compared the safety and efficacy of first-generation versus second-generation Food and Drug Administration approved DES; the following devices were included: first-generation sirolimus-eluting stent (SES) and paclitaxel-eluting stents (PES); second-generation everolimus-eluting stent (EES), zotarolimus-eluting stent Endeavor and ZES-Resolute (ZES-R). Prespecified safety end points comprised ≤1 and >1 year: overall and cardiac mortality, myocardial infarction (MI), definite/definite or probable ST; efficacy end points were target lesion revascularisation and target vessel revascularisation. Composite end points wer...
2022
This record contains raw data related to the article: Gender-associated outcomes following percutaneous coronary intervention with a third-generation, ultrathin-strut drug-eluting stent: a real-world, single-center experience. ABSTRACT <strong>Introduction.</strong> In recent years the new third-generation, ultrathin bioresorbable-polymer sirolimus-eluting stent (BP-SES), characterized by some of the thinnest struts among commercially available devices (60-80 µm) and an amorphous silicon carbide coating, has been introduced for the treatment of coronary artery disease (CAD). Aim of the present study was to assess different clinical outcomes and safety of this drug-eluting stent in male and female patients in a real-world setting. <strong>Methods. </strong>The present study is a retrospective analysis including all patients treated with BP-SES between January 2017 and December 2019 at a single, high-volume center. Follow-up was performed by outpatient visit or...